Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic tetrapeptide
An experimental peptide marketed around liver-health and aging-related claims. It is not an FDA-approved liver treatment.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Relay did not locate a modern controlled human trial establishing clinical liver outcomes from administered KEDA.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Current evidence cannot yet resolve: Human exposure, bioavailability, clinically meaningful liver outcomes, product identity, and longer-term safety.
No direct evidenceAn absence of adequate evidence is not evidence of benefit, harm, or equivalence.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryNot FDA-approved; human clinical evidence for administered Livagen is not established. Human exposure, bioavailability, clinically meaningful liver outcomes, product identity, and longer-term safety.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
The reviewed cellular and chromatin findings do not establish a human administered dose or clinically effective course.
What would fill this gap: A primary human administration study of the exact Livagen peptide.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Published research investigated KEDA-containing interventions in aged rats and measured digestive-enzyme activity during a short preclinical treatment course.
Population: Aged rats
Design: Controlled animal study
Mechanisms
KEDA studies explore transcriptional and tissue effects, but the direct administered-human evidence base is sparse and regionally concentrated.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Laboratory and animal evidence with limited older human-associated reports.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Human exposure, bioavailability, clinically meaningful liver outcomes, product identity, and longer-term safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: No verified modern controlled human trial established clinical liver outcomes from administered KEDA. Animal enzyme changes cannot establish liver targeting, symptom improvement, disease modification, human exposure, or safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled animal study
Aged rats
Endpoints were not fully described in the current record.
KEDA-containing experiments evaluated digestive-enzyme activity in aged animal models.
Study administration: Not stated in the current record.
Limitations: Animal enzyme changes do not establish human liver benefit.
Human-cell culture study
Population not stated.
Endpoints were not fully described in the current record.
Laboratory work examined short-peptide effects in cultured human cells.
Study administration: Not stated in the current record.
Limitations: No administered-human outcome evidence.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 16075683
PMID 25051766